Akebia Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Akebia Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Akebia Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Akebia Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Akebia Therapeutics Inc (Akebia Therapeutics) is a commercial-stage biopharmaceutical company. It develops and commercializes novel therapeutics based on hypoxia-inducible factors for patients with kidney disease and other metabolic disorders. The company’s product portfolio includes vadadustat, that treats dialysis-dependent chronic kidney disease (DD-CKD) and non-dialysis-dependent chronic kidney disease (NDD-CKD); ferric citrate targeting hyperphosphatemia and iron deficiency anemia; AKB-9090 for acute kidney injury and acute respiratory distress syndrome; and AKB-10108, that treats retinopathy of prematurity. It operates through its subsidiaries in the US, Ireland and the UK. Akebia Therapeutics is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
245 First Street, Cambridge, Massachusetts, 02142
Website
akebia.com
Telephone
1 617 8712098
No of Employees
194
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
AKBA (NASD)
Revenue (2024)
$236.2M
47.5%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
92.3%
(2024 vs 2023)
Market Cap*
$305.8M
Net Profit Margin (2024)
XYZ
94.8%
(2024 vs 2023)
* As of and is in US$
Akebia Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Vadadustat: | Auryxia |
| Dialysis-Dependent Chronic Kidney Disease | Vafseo |
| Non-Dialysis Dependent Chronic Kidney Disease | Akebia Therapeutics |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Acquisitions/Mergers/Takeovers | In December, the company acquired rights to AKB-097, a tissue-targeted C3d-Factor H fusion protein complement inhibitor, from Q32 Bio Inc. |
| 2025 | New Products/Services | In December, the company launched a pipeline for rare kidney disease centered on two core product candidates: AKB-097 (formerly ADX-097), a potential next-generation complement inhibitor, and praliciguat, a soluble guanylate cyclase stimulator. |
| 2025 | New Products/Services | In August, the company and Innovative Renal Care launched Vafseo (vadadustat) to treat anemia. |
Competitor Comparison
| Key Parameters | Akebia Therapeutics Inc | Johnson & Johnson | Roche Holding AG | Pfizer Inc | Sanofi |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Switzerland | United States of America | France |
| City | Cambridge | New Brunswick | Basel | New York City | Paris |
| State/Province | Massachusetts | New Jersey | Basel-Stadt | New York | Ile-de-France |
| No. of Employees | 194 | 138,200 | 112,774 | 75,000 | 76,493 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Adrian Adams | Chairman | Executive Board | 2018 | 75 |
| John P. Butler | President; Director; Chief Executive Officer | Executive Board | 2013 | 61 |
| Erik J. Ostrowski | Chief Business Officer; Senior Vice President; Chief Financial Officer | Senior Management | 2024 | 53 |
| Justin McCue, Ph.D. | Senior Vice President; Chief Technology Officer | Senior Management | 2026 | - |
| Carolyn M. Rucci | Secretary; Senior Vice President; Chief Legal Officer | Senior Management | 2021 | 45 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer